Publications by authors named "L Letona"
Host biomarkers for early identification of severe imported Plasmodium falciparum malaria.
Travel Med Infect Dis
November 2023
Background: Severe imported P. falciparum malaria is a source of morbi-mortality in non-endemic regions. WHO criteria don't accurately classify patients at risk of complications.
View Article and Find Full Text PDFObjectives: We described the current incidence and risk factors of bacterial co-infection in hospitalized patients with COVID-19.
Methods: Observational cohort study was performed at the Hospital Clinic of Barcelona (February 2020-February 2021). All patients with COVID-19 who were admitted for >48 hours with microbiological sample collection and procalcitonin (PCT) determination within the first 48 hours were included.
Article Synopsis
- The study investigated how treatments like anti-IL-6 biologics and corticosteroids affect the risk of hospital-acquired infections in COVID-19 patients.
- A case-control framework was used, comparing 71 COVID-19 patients with infections to 142 matched controls without infections.
- Key findings highlighted that severe comorbidities, like chronic liver disease and invasive mechanical ventilation, dramatically increased infection risk, while inflammatory response modifiers showed no impact on hospital-acquired infections.
Objective: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare.
Methods: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab.
Results: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males.